{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T06:33:42Z","timestamp":1791614022019,"version":"4.3.4"},"reference-count":84,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.critrevonc.2025.104770","type":"journal-article","created":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T19:20:43Z","timestamp":1747941643000},"page":"104770","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Secondary mutational and cytogenetic alterations in core binding factor \u2013 Acute myeloid leukemia (CBF-AML): A systematic review and meta-analysis"],"prefix":"10.1016","volume":"212","author":[{"given":"Amin","family":"Javidan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3399-2360","authenticated-orcid":false,"given":"Alireza","family":"Azarboo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayeh","family":"Jalali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parisa","family":"Fallahtafti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeganeh","family":"Azimi Shahrabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjan","family":"Yaghmaie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir T.","family":"Fathi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9865","key":"10.1016\/j.critrevonc.2025.104770_bib1","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/S0140-6736(12)61727-9","article-title":"Acute myeloid leukaemia in adults","volume":"381","author":"Ferrara","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2025.104770_bib2","unstructured":"Chennamadhavuni A., Lyengar V., Mukkamalla S.K.R., Shimanovsky A. Leukemia. StatPearls. Treasure Island (FL): StatPearls Publishing. Copyright \u00a9 2024, StatPearls Publishing LLC.; 2024."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104770_bib3","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0261871","article-title":"The epidemiology, treatment patterns, healthcare utilizations and costs of Acute Myeloid Leukaemia (AML) in Taiwan","volume":"17","author":"Huang","year":"2022","journal-title":"PLoS One"},{"issue":"20","key":"10.1016\/j.critrevonc.2025.104770_bib4","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1182\/blood-2015-12-688705","article-title":"Comprehensive mutational profiling of core binding factor acute myeloid leukemia","volume":"127","author":"Duployez","year":"2016","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.critrevonc.2025.104770_bib5","doi-asserted-by":"crossref","first-page":"21592","DOI":"10.1002\/cam4.6693","article-title":"Clinical characteristics and prognostic factors analysis of core binding factor acute myeloid leukemia in real world","volume":"12","author":"Zhai","year":"2023","journal-title":"Cancer Med"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104770_bib6","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1182\/bloodadvances.2019000709","article-title":"Prospective evaluation of prognostic impact of KIT mutations on acute myeloid leukemia with RUNX1-RUNX1T1 and CBFB-MYH11","volume":"4","author":"Ishikawa","year":"2020","journal-title":"Blood Adv."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104770_bib7","article-title":"Therapy-related core binding factor acute myeloid leukemia","volume":"12","author":"George","year":"2023","journal-title":"Int J. Hematol. Oncol."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104770_bib8","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1182\/bloodadvances.2020003605","article-title":"Secondary cytogenetic abnormalities in core-binding factor AML harboring inv(16) vs t(8;21)","volume":"5","author":"Han","year":"2021","journal-title":"Blood Adv."},{"key":"10.1016\/j.critrevonc.2025.104770_bib9","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/1471-2288-14-45","article-title":"Newcastle-Ottawa Scale: comparing reviewers' to authors' assessments","volume":"14","author":"Lo","year":"2014","journal-title":"BMC Med Res Method."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104770_bib10","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1080\/10428194.2019.1709836","article-title":"Loss of X chromosome predicts favorable prognosis in female patients with t(8;21) acute myeloid leukemia","volume":"61","author":"Chen","year":"2020","journal-title":"Leuk. Lymphoma"},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104770_bib11","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2016.51","article-title":"Next-generation sequencing with a myeloid gene panel in core-binding factor AML showed KIT activation loop and TET2 mutations predictive of outcome","volume":"6","author":"Cher","year":"2016","journal-title":"Blood Cancer J."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104770_bib12","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1186\/s12967-019-1926-z","article-title":"High IL2RA mRNA expression is an independent adverse prognostic biomarker in core binding factor and intermediate-risk acute myeloid leukemia","volume":"17","author":"Du","year":"2019","journal-title":"J. Transl. Med"},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104770_bib13","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1007\/s00277-021-04432-z","article-title":"Both the subtypes of KIT mutation and minimal residual disease are associated with prognosis in core binding factor acute myeloid leukemia: a retrospective clinical cohort study in single center","volume":"100","author":"Duan","year":"2021","journal-title":"Ann. Hematol."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104770_bib14","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0124241","article-title":"High expression of c-kit mRNA predicts unfavorable outcome in adult patients with t(8;21) acute myeloid leukemia","volume":"10","author":"Gao","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.critrevonc.2025.104770_bib15","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s40880-016-0110-6","article-title":"Low WT1 transcript levels at diagnosis predicted poor outcomes of acute myeloid leukemia patients with t(8;21) who received chemotherapy or allogeneic hematopoietic stem cell transplantation","volume":"35","author":"Qin","year":"2016","journal-title":"Chin. J. Cancer"},{"issue":"12","key":"10.1016\/j.critrevonc.2025.104770_bib16","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1016\/j.leukres.2014.09.017","article-title":"Prevalence and prognostic significance of c-KIT mutations in core binding factor acute myeloid leukemia: a comprehensive large-scale study from a single Chinese center","volume":"38","author":"Qin","year":"2014","journal-title":"Leuk. Res"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104770_bib17","doi-asserted-by":"crossref","DOI":"10.1002\/hon.3264","article-title":"Usefulness of KIT mutant transcript levels for monitoring measurable residual disease in t (8;21) acute myeloid leukemia","volume":"42","author":"Sun","year":"2024","journal-title":"Hematol. Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104770_bib18","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.clml.2021.11.013","article-title":"Differential Implications of CSF3R Mutations in t(8;21) and CEBPA Double Mutated Acute Myeloid Leukemia","volume":"22","author":"Wang","year":"2022","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104770_bib19","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.bbrc.2012.10.069","article-title":"Integrative analysis of prognostic factors in Chinese core binding factor leukemia","volume":"428","author":"Wang","year":"2012","journal-title":"Biochem Biophys. Res Commun."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104770_bib20","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s12288-021-01507-9","article-title":"Prognostic factors in acute myeloid leukemia with t(8;21)\/AML1-ETO: strategies to define high-risk patients","volume":"38","author":"Wang","year":"2022","journal-title":"Indian J. Hematol. Blood Transfus."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104770_bib21","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1080\/10428194.2021.1966785","article-title":"Prognostic significance of TIM-3 expression pattern at diagnosis in patients with t(8;21) acute myeloid leukemia","volume":"63","author":"Wang","year":"2022","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.critrevonc.2025.104770_bib22","article-title":"CALCRL gene is a suitable prognostic factor in AML\/ETO(+) AML patients","volume":"2022","author":"Wang","year":"2022","journal-title":"J. Oncol."},{"issue":"12","key":"10.1016\/j.critrevonc.2025.104770_bib23","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1182\/blood-2014-03-563403","article-title":"In adults with t(8;21)AML, posttransplant RUNX1\/RUNX1T1-based MRD monitoring, rather than c-KIT mutations, allows further risk stratification","volume":"124","author":"Wang","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2025.104770_bib24","article-title":"Low IL7R expression at diagnosis predicted relapse in adult acute myeloid leukemia patients with t(8;21)","volume":"13","author":"Xu","year":"2022","journal-title":"Front Immunol."},{"issue":"11","key":"10.1016\/j.critrevonc.2025.104770_bib25","first-page":"8032","article-title":"Increased expression of miR-24 is associated with acute myeloid leukemia with t(8;21)","volume":"7","author":"Yin","year":"2014","journal-title":"Int J. Clin. Exp. Pathol."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104770_bib26","first-page":"2333","article-title":"Gene mutation profile and risk stratification in AML1\u2011ETO\u2011positive acute myeloid leukemia based on next\u2011generation sequencing","volume":"42","author":"Yu","year":"2019","journal-title":"Oncol. Rep."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104770_bib27","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1080\/10428194.2019.1683734","article-title":"Loss of the Y chromosome predicts a high relapse risk in younger adult male patients with t(8;21) acute myeloid leukemia on high-dose cytarabine consolidation therapy: a retrospective multicenter study","volume":"61","author":"Zhou","year":"2020","journal-title":"Leuk. Lymphoma"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104770_bib28","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1080\/16078454.2022.2056982","article-title":"The favorable prognostic value of the loss of sex chromosomes in patients with t(8;21) acute myeloid leukemia: an exploratory study","volume":"27","author":"Zhu","year":"2022","journal-title":"Hematology"},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104770_bib29","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/j.leukres.2011.01.014","article-title":"RAD51 and XRCC3 polymorphisms: impact on the risk and treatment outcomes of de novo inv(16) or t(16;16)\/CBF\u03b2-MYH11(+) acute myeloid leukemia","volume":"35","author":"Liu","year":"2011","journal-title":"Leuk. Res"},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104770_bib30","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1002\/hon.3015","article-title":"Combination of KIT and FLT3-ITD mutation status with minimal residual disease levels guides treatment strategy for adult patients with inv(16) acute myeloid leukemia in first complete remission","volume":"40","author":"Wang","year":"2022","journal-title":"Hematol. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104770_bib31","article-title":"Risk factors for post-transplant relapse and survival in younger adult patients with t(8;21)(q22;q22) acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation: a multicenter retrospective study","volume":"13","author":"Zhou","year":"2023","journal-title":"Front Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104770_bib32","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13020336","article-title":"Prognostic impacts of D816V KIT mutation and peri-transplant RUNX1-RUNX1T1 MRD monitoring on acute myeloid leukemia with RUNX1-RUNX1T1","volume":"13","author":"Cho","year":"2021","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104770_bib33","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2015.116","article-title":"Significance of KIT exon 17 mutation depends on mutant level rather than positivity in core-binding factor acute myeloid leukemia","volume":"6","author":"Jang","year":"2016","journal-title":"Blood Cancer J."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104770_bib34","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s00277-012-1580-5","article-title":"KIT D816 mutation associates with adverse outcomes in core binding factor acute myeloid leukemia, especially in the subgroup with RUNX1\/RUNX1T1 rearrangement","volume":"92","author":"Kim","year":"2013","journal-title":"Ann. Hematol."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104770_bib35","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1016\/j.leukres.2011.06.003","article-title":"Prognostic impact of c-KIT mutations in core binding factor acute myeloid leukemia","volume":"35","author":"Park","year":"2011","journal-title":"Leuk. Res"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104770_bib36","doi-asserted-by":"crossref","first-page":"288","DOI":"10.3343\/alm.2015.35.3.288","article-title":"Incidences and Prognostic Impact of c-KIT, WT1, CEBPA, and CBL Mutations, and Mutations Associated With Epigenetic Modification in Core Binding Factor Acute Myeloid Leukemia: A Multicenter Study in a Korean Population","volume":"35","author":"Park","year":"2015","journal-title":"Ann. Lab Med"},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104770_bib37","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1007\/s00277-019-03624-y","article-title":"Different prognostic effects of core-binding factor positive AML with Korean AML registry data","volume":"98","author":"Shin","year":"2019","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.critrevonc.2025.104770_bib38","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.783114","article-title":"A predictor combining clinical and genetic factors for AML1-ETO leukemia patients","volume":"11","author":"Yang","year":"2022","journal-title":"Front Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104770_bib39","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s00277-018-3492-5","article-title":"Clinical significance of ASXL2 and ZBTB7A mutations and C-terminally truncated RUNX1-RUNX1T1 expression in AML patients with t(8;21) enrolled in the JALSG AML201 study","volume":"98","author":"Kawashima","year":"2019","journal-title":"Ann. Hematol."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104770_bib40","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/sj.leu.2402871","article-title":"Characteristics of t(8;21) acute myeloid leukemia (AML) with additional chromosomal abnormality: concomitant trisomy 4 may constitute a distinctive subtype of t(8;21) AML","volume":"17","author":"Nishii","year":"2003","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104770_bib41","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1007\/s00277-017-3074-y","article-title":"D816 mutation of the KIT gene in core binding factor acute myeloid leukemia is associated with poorer prognosis than other KIT gene mutations","volume":"96","author":"Yui","year":"2017","journal-title":"Ann. Hematol."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104770_bib42","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1007\/s12185-021-03238-z","article-title":"Non-age-related neoplastic loss of sex chromosome correlated with prolonged survival in real-world CBF-AML patients","volume":"115","author":"Mori","year":"2022","journal-title":"Int J. Hematol."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104770_bib43","article-title":"Cytogenetic analysis of acute myeloid leukemia with t(8;21): its clinical correlation with loss of X chromosome and Del (9q)","volume":"9","author":"Abd El Ghafar","year":"2018","journal-title":"J. Appl. Hematol."},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104770_bib44","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.clml.2020.02.002","article-title":"Outcome of core binding factor acute myeloid leukemia by receptor tyrosine kinase mutation","volume":"20","author":"Alnagar","year":"2020","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.critrevonc.2025.104770_bib45","first-page":"20","article-title":"Detection of KIT mutations in core binding factor acute myeloid leukemia","volume":"10","author":"Badr","year":"2018","journal-title":"Leuk. Res Rep."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104770_bib46","first-page":"9","article-title":"Prognostic implication of N-RAS gene mutations in Egyptian adult acute myeloid leukemia","volume":"16","author":"Elghannam","year":"2009","journal-title":"Egypt J. Immunol."},{"issue":"9","key":"10.1016\/j.critrevonc.2025.104770_bib47","doi-asserted-by":"crossref","first-page":"3463","DOI":"10.1182\/blood-2005-09-3640","article-title":"Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study","volume":"107","author":"Cairoli","year":"2006","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104770_bib48","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.3892\/or.2013.2328","article-title":"Core binding factor acute myeloid leukaemia and c-KIT mutations","volume":"29","author":"Riera","year":"2013","journal-title":"Oncol. Rep."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104770_bib49","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1038\/leu.2016.332","article-title":"Mutations in the CCND1 and CCND2 genes are frequent events in adult patients with t(8;21)(q22;q22) acute myeloid leukemia","volume":"31","author":"Eisfeld","year":"2017","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104770_bib50","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1038\/modpathol.2008.92","article-title":"Acute myeloid leukemia harboring t(8;21)(q22;q22): a heterogeneous disease with poor outcome in a subset of patients unrelated to secondary cytogenetic aberrations","volume":"21","author":"Lin","year":"2008","journal-title":"Mod. Pathol."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104770_bib51","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1182\/bloodadvances.2019000492","article-title":"Combination of dasatinib with chemotherapy in previously untreated core binding factor acute myeloid leukemia: CALGB 10801","volume":"4","author":"Marcucci","year":"2020","journal-title":"Blood Adv."},{"issue":"24","key":"10.1016\/j.critrevonc.2025.104770_bib52","doi-asserted-by":"crossref","first-page":"3904","DOI":"10.1200\/JCO.2006.06.9500","article-title":"Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study","volume":"24","author":"Paschka","year":"2006","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104770_bib53","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1002\/cncr.25670","article-title":"Prognostic value of FLT3 mutations among different cytogenetic subgroups in acute myeloid leukemia","volume":"117","author":"Santos","year":"2011","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104770_bib54","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1182\/blood-2012-07-442772","article-title":"inv(16)\/t(16;16) acute myeloid leukemia with non-type A CBFB-MYH11 fusions associate with distinct clinical and genetic features and lack KIT mutations","volume":"121","author":"Schwind","year":"2013","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104770_bib55","doi-asserted-by":"crossref","first-page":"3847","DOI":"10.1182\/blood-2005-08-3522","article-title":"Implications of NRAS mutations in AML: a study of 2502 patients","volume":"107","author":"Bacher","year":"2006","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104770_bib56","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1182\/blood-2018-05-852822","article-title":"Genomic landscape and clonal evolution of acute myeloid leukemia with t(8;21): an international study on 331 patients","volume":"133","author":"Christen","year":"2019","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104770_bib57","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms11733","article-title":"ZBTB7A mutations in acute myeloid leukaemia with t(8;21) translocation","volume":"7","author":"Hartmann","year":"2016","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104770_bib58","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1038\/leu.2017.18","article-title":"Incidence and prognostic impact of ASXL2 mutations in adult acute myeloid leukemia patients with t(8;21)(q22;q22): a study of the German-Austrian AML Study Group","volume":"31","author":"Jahn","year":"2017","journal-title":"Leukemia"},{"issue":"24","key":"10.1016\/j.critrevonc.2025.104770_bib59","doi-asserted-by":"crossref","first-page":"6342","DOI":"10.1182\/bloodadvances.2020002673","article-title":"Genomic heterogeneity in core-binding factor acute myeloid leukemia and its clinical implication","volume":"4","author":"Jahn","year":"2020","journal-title":"Blood Adv."},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104770_bib60","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1038\/leu.2014.4","article-title":"High number of additional genetic lesions in acute myeloid leukemia with t(8;21)\/RUNX1-RUNX1T1: frequency and impact on clinical outcome","volume":"28","author":"Krauth","year":"2014","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104770_bib61","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/s41375-019-0578-6","article-title":"Functional characterization of BRCC3 mutations in acute myeloid leukemia with t(8;21)(q22;q22.1)","volume":"34","author":"Meyer","year":"2020","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104770_bib62","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1182\/blood-2012-05-431486","article-title":"Secondary genetic lesions in acute myeloid leukemia with inv(16) or t(16;16): a study of the German-Austrian AML Study Group (AMLSG)","volume":"121","author":"Paschka","year":"2013","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104770_bib63","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1038\/s41375-019-0697-0","article-title":"The clinical mutatome of core binding factor leukemia","volume":"34","author":"Opatz","year":"2020","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.critrevonc.2025.104770_bib64","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1182\/blood-2012-10-462879","article-title":"Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia","volume":"121","author":"Jourdan","year":"2013","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.critrevonc.2025.104770_bib65","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1182\/blood-2014-04-571018","article-title":"Frequent ASXL2 mutations in acute myeloid leukemia patients with t(8;21)\/RUNX1-RUNX1T1 chromosomal translocations","volume":"124","author":"Micol","year":"2014","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104770_bib66","doi-asserted-by":"crossref","first-page":"458","DOI":"10.2353\/jmoldx.2009.090043","article-title":"Rapid detection of KIT mutations in core-binding factor acute myeloid leukemia using high-resolution melting analysis","volume":"11","author":"Fuster","year":"2009","journal-title":"J. Mol. Diagn."},{"issue":"9","key":"10.1016\/j.critrevonc.2025.104770_bib67","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1038\/leu.2013.186","article-title":"The importance of relative mutant level for evaluating impact on outcome of KIT, FLT3 and CBL mutations in core-binding factor acute myeloid leukemia","volume":"27","author":"Allen","year":"2013","journal-title":"Leukemia"},{"issue":"18","key":"10.1016\/j.critrevonc.2025.104770_bib68","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.1200\/JCO.2004.03.012","article-title":"Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup","volume":"22","author":"Schlenk","year":"2004","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104770_bib69","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1002\/ajh.23461","article-title":"Old and new prognostic factors in acute myeloid leukemia with deranged core-binding factor beta","volume":"88","author":"Cairoli","year":"2013","journal-title":"Am. J. Hematol."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104770_bib70","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1152\/physrev.00046.2011","article-title":"Stem cell factor receptor\/c-Kit: from basic science to clinical implications","volume":"92","author":"Lennartsson","year":"2012","journal-title":"Physiol. Rev."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104770_bib71","first-page":"1003","article-title":"Primary structure of c-kit: relationship with the CSF-1\/PDGF receptor kinase family--oncogenic activation of v-kit involves deletion of extracellular domain and C terminus. Embo j","volume":"7","author":"Qiu","year":"1988"},{"key":"10.1016\/j.critrevonc.2025.104770_bib72","doi-asserted-by":"crossref","first-page":"785","DOI":"10.2147\/OTT.S404648","article-title":"c-kit receptors as a therapeutic target in cancer: current insights","volume":"16","author":"Abdellateif","year":"2023","journal-title":"Onco Targets Ther."},{"issue":"11","key":"10.1016\/j.critrevonc.2025.104770_bib73","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1016\/j.biocel.2006.12.005","article-title":"c-Kit--a hematopoietic cell essential receptor tyrosine kinase","volume":"39","author":"Edling","year":"2007","journal-title":"Int J. Biochem Cell Biol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104770_bib74","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1634\/stemcells.2004-0117","article-title":"Normal and oncogenic forms of the receptor tyrosine kinase kit","volume":"23","author":"Lennartsson","year":"2005","journal-title":"Stem Cells"},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104770_bib75","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1038\/leu.2011.34","article-title":"A phase I\/II study of imatinib plus reinduction therapy for c-kit-positive relapsed\/refractory acute myeloid leukemia: inhibition of Akt activation correlates with complete response","volume":"25","author":"Brandwein","year":"2011","journal-title":"Leukemia"},{"issue":"22","key":"10.1016\/j.critrevonc.2025.104770_bib76","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1182\/blood.2021011582","article-title":"Depalmitoylation rewires FLT3-ITD signaling and exacerbates leukemia progression","volume":"138","author":"Lv","year":"2021","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.critrevonc.2025.104770_bib77","doi-asserted-by":"crossref","first-page":"954","DOI":"10.18632\/oncotarget.652","article-title":"Mutations and deregulation of Ras\/Raf\/MEK\/ERK and PI3K\/PTEN\/Akt\/mTOR cascades which alter therapy response","volume":"3","author":"McCubrey","year":"2012","journal-title":"Oncotarget"},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104770_bib78","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1080\/10428194.2023.2190432","article-title":"Impact of KRAS and NRAS mutations on outcomes in acute myeloid leukemia","volume":"64","author":"Mustafa Ali","year":"2023","journal-title":"Leuk. Lymphoma"},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104770_bib79","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/sj.leu.2404624","article-title":"MD. A tumor suppressor and oncogene: the WT1 story","volume":"21","author":"Yang","year":"2007","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104770_bib80","doi-asserted-by":"crossref","first-page":"672","DOI":"10.3324\/haematol.2015.141796","article-title":"Wilms tumor 1 mutations in the pathogenesis of acute myeloid leukemia","volume":"101","author":"Rampal","year":"2016","journal-title":"Haematologica"},{"issue":"11","key":"10.1016\/j.critrevonc.2025.104770_bib81","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1080\/17474086.2019.1657400","article-title":"Trisomy 8 in acute myeloid leukemia","volume":"12","author":"Hemsing","year":"2019","journal-title":"Expert Rev. Hematol."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104770_bib82","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1111\/ejh.13037","article-title":"MLL-rearranged acute myeloid leukemia: influence of the genetic partner in allo-HSCT response and prognostic factor of MLL 3\u2032 region mRNA expression","volume":"100","author":"Burillo-Sanz","year":"2018","journal-title":"Eur. J. Haematol."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104770_bib83","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1159\/000525010","article-title":"Genomic features of interstitial deletions of chromosome 9q in acute myeloid leukemia","volume":"162","author":"Qi","year":"2022","journal-title":"Cytogenet Genome Res."},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104770_bib84","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25084230","article-title":"Loss of the Y chromosome: a review of molecular mechanisms, age inference, and implications for men's health","volume":"25","author":"Guti\u00e9rrez-Hurtado","year":"2024","journal-title":"Int. J. Mol. Sci."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825001581?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825001581?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T00:18:37Z","timestamp":1752711517000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842825001581"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":84,"alternative-id":["S1040842825001581"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104770","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Secondary mutational and cytogenetic alterations in core binding factor \u2013 Acute myeloid leukemia (CBF-AML): A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104770","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104770"}}